What's Happening?
The National Institute for Health and Care Excellence (NICE) has recommended the use of pirtobrutinib, a take-at-home tablet, for patients with chronic lymphocytic leukaemia (CLL) in England. This recommendation is specifically for patients who have previously
been treated with a covalent Bruton’s tyrosine kinase inhibitor (BTKi) and for whom further treatment with a covalent BTKi is not suitable. Pirtobrutinib, an oral medication, offers a new treatment option that reduces the need for hospital visits, providing a more convenient alternative to infusional treatment regimens. The draft guidance highlights that pirtobrutinib is cost-effective compared to other treatments like venetoclax alone or in combination with rituximab. However, it can only be used if further treatment with a BTKi is not clinically suitable. The consultation on this draft guidance is open until May 11, 2026.
Why It's Important?
This development is significant as it introduces a more accessible treatment option for CLL patients, potentially improving their quality of life by minimizing hospital visits. The approval of pirtobrutinib could alleviate pressure on healthcare facilities by reducing the demand for infusional therapies. For patients, especially those with relapsing-remitting conditions, this oral treatment offers greater autonomy and flexibility in managing their condition. From a healthcare system perspective, the use of oral agents like pirtobrutinib may help reduce the strain on day units and preparation services, which are already under significant pressure.
What's Next?
The draft guidance is currently open for consultation, and stakeholders, including healthcare professionals and patient groups, are likely to provide feedback. If the guidance is finalized, healthcare providers in England will begin prescribing pirtobrutinib to eligible patients. This could lead to further evaluations of its effectiveness and cost-efficiency in real-world settings, potentially influencing treatment protocols for CLL in other regions.
